All In MedTech

Device Trial Radar · NCT06268288

Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)

Pilot Study--The Effects of Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)

Last checked: Nov 20, 2026Latest source record: Oct 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Feb 14, 2024

Primary completion

Oct 5, 2024

Study completion Oct 5, 2024

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 20, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 12 years, up to 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if nVNS will decrease autonomic symptom intensity (COMPASS-31 and Child Functional Disability Inventory) in adolescent patients with postural orthostatic tachycardia syndrome (POTS) in comparison to standard recovery STEPS management.

Conditions

  • Postural Tachycardia Syndrome
  • Autonomic Dysfunction
  • Postural Orthostatic Tachycardia Syndrome
  • POTS - Postural Orthostatic Tachycardia Syndrome

Interventions

  • GammaCore interventionDevice

    Use of the vagal nerve stimulator, GammaCore, on the right side of the neck for two 2 minute stimulations performed 3 times a day

  • STEPS management protocolOther

    STEPS is the acronym for the standard management program for our patients with POTS. It includes liberal use of salt, taking in 90-100 ounces of fluid, gradually increasing the duration of aerobic exercise, possible use of one of two prescription medications (metoprolol, and midodrine), and encouragement to set priority and goals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Change in Composite Autonomic Symptom Score (COMPASS-31)Time frame: Baseline; 8 Weeks

2 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.